Deep Biotech: disruptive innovation for global sustainability

Maddie Cass.png

Deep Biotech applies the power of biotechnology to address some of humanity's biggest challenges. The life sciences industry has ushered in many ground-breaking innovations in health. In response to the challenge of global warming the same technologies that delivered life-saving therapeutics are being harnessed to disrupt traditional industries and reduce environmental damage.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, reports on the expansion of the BIA’s activities to serve at the front line of this transformation.

What is Deep Biotech?

The BIA has coined a new term ‘Deep Biotech’ to describe the application of modern biotechnologies to humanity's most profound challenges beyond health, including climate change, pollution and food security. Our growing ability to precisely edit DNA and engineer biology to do new things provides us with an entirely new toolkit to solve problems, just as chemistry did in the 19th Century and physics did in the 20th Century.

As with other instances of deep tech, it is a long-term investment requiring complex scientific research and advanced engineering to reach revolutionary breakthroughs that empower multiple industries to address urgent issues.

This biological innovation is propelling us into what is often referred to as the Fourth Industrial Revolution, the biorevolution. Underpinning this revolution is the continued development of modern, disruptive biotechnologies such as engineering biology, and their purposeful application. Deep Biotech has the potential to unleash the biorevolution and realise UK and global ambitions to create a sustainable bioeconomy. The BIA’s growing Deep Biotech membership is part of that revolution.

Organisations and governments turn to biotech to help them address sustainability challenges

Globally, the impacts of climate change are clear and people, organisations and governments around the world understand the need to make changes to safeguard our future. Innovative biotechnology is seen as a key tool to help us tackle climate change and meet the UN’s Sustainable Development Goals. Multinational companies like Lego are turning to biobased solutions to help green their supply chains.

The UK Government is aware of the scientific and engineering innovations needed to counteract the impacts of global warming. Recent government activity and increased interest in the field of engineering biology, identified as a critical technology, will underpin the transformation towards a more sustainable future.

The Department for Science, Innovation, and Technology (DSIT) recently sought input to a consultation from innovators across business and academic communities to shape coherent UK policy that will support the engineering biology ecosystem, from foundational research through to consumer facing products. The BIA submitted a substantial response to the consultation, building on the already-close relationship we have with DSIT to further the uptake of engineering biology and adoption of Deep Biotech solutions.

Innovative solutions are disrupting the market

UK SMEs are charting the way forward by introducing disruptive biotechnologies to the market. These innovative technologies include:

  • Engineered microbes capable of producing enzymes that efficiently and sustainably break down non-biodegradable materials like plastics. This could revolutionise traditional recycling by transforming plastic waste into a valuable source of new materials, thus driving the circular bioeconomy.
  • Precision breeding, made possible through gene editing, enhances crops with traits such as pest resistance, drought tolerance, and enhanced nutritional content. The recent Genetic Technology Act is a first step towards securing food security with the potential to minimise agriculture's environmental footprint.
  • Cellular agriculture is the practice of cultivating meat, seafood, milk and eggs from cells, removing the environmental burdens of industrial-scale farming. It heralds a more sustainable and ethical future for food production.
  • Biofuels are helping hard-to-decarbonise industries like aviation and shipping meet Net Zero targets. Engineering biology is delivering the next generation of biofuels through genetically engineered crops, or new efficient pathways to transform biowaste into feedstock.
  • Novel textiles and materials can ease our reliance on fossil fuels to make clothing and plastics. Bacteria, fungi and food waste are all being developed as sources to create new fabrics and materials that will challenge the existing industries.
  • Bioremediation restores contaminated environments by harnessing the power of microbes to degrade and detoxify pollutants. These organisms are engineered to breakdown or stabilise contaminants safely, allowing us to clean up polluted natural spaces, restore fertile farmland, and develop abandoned brownfield sites.

BIA will influence, connect, and save for Deep Biotech

Leveraging our extensive experience in supporting the UK's health biotech sector, the BIA is committed to assisting Deep Biotech companies which are at the forefront of applying disruptive biotechnologies beyond healthcare. Working in close consultation with our growing Deep Biotech membership, we are actively developing our activities in this space to empower companies working to tackling some of our world’s most challenging problems, enabling them to start, grow and deliver world-changing innovation in the UK.

We will be publishing a detailed report early next year exploring and characterising this exciting and growing community of companies, and rolling out a range of activities throughout 2024 to support and represent them.

If you are interested to learn more about the BIA’s work in this space, or if you are a member interested in joining our Deep Biotech group, please contact Policy and Public Affairs Manager, Linda Bedenik.


More news and updates 

The UK's genomics sector: Poised for continued growth and impact

Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.

CEO Update - 4 December 2023

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.

bioProcessUK 2023: Honouring excellence, unveiling future leaders 

In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.

CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.

Autumn Statement 2023 analysis

The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

Member spotlight: meet the Bio-Based and Biodegradable Industries Association

The Bio-Based and Biodegradable Industries Association (BBIA) and The BioIndustry Association (BIA) enter a mutual membership agreement to strengthen collaboration and support each other's work and member communities.

Bioprocessing: Unraveling the future by examining the past

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation.

CEO Update - 20 November 2023

London Life Sciences Week last week had an amazing buzz. I think there were more Americans in life science over for one week than I’ve ever experienced – centred on the Jefferies Healthcare Conference. At the same time, London was also full of Europeans at events like the Scrip Awards, where Jeremy Levin received the Lifetime Achievement Award and gave an impactful speech. The connectivity was immense - with a massive range of events that were really vibrant, diverse and inclusive.

London Life Sciences Week: connecting the global biotech community

London Life Sciences Week united the global biotech community for a dynamic week of networking and dealmaking. The BIA representatives were out and about throughout the week, networking with members and stakeholders. In this blog, Steve Bates OBE, CEO of BioIndustry Association, summarises insights based on the BIA team's first-hand experience.


More within